行情

PDLI

PDLI

PDL BioPharma
NASDAQ

实时行情|Nasdaq Last Sale

3.480
+0.010
+0.29%
盘后: 3.480 0 0.00% 16:00 02/21 EST
开盘
3.490
昨收
3.470
最高
3.490
最低
3.420
成交量
94.70万
成交额
--
52周最高
3.890
52周最低
2.060
市值
3.97亿
市盈率(TTM)
-125.1799
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PDLI价格均价为3.000,最高价位3.000,最低价为3.000。

EPS

PDLI 新闻

更多
  • Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
  • Zacks · 01/29 16:11
  • AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
  • Zacks · 01/28 15:39
  • Lower prices take shine off Petra Diamonds revenue
  • MarketWatch · 01/27 15:43
  • Axsome (AXSM) Completes Patient Randomization in TRD Study
  • Zacks · 01/23 14:34

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

PDLI 简况

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
展开

微牛提供PDL BioPharma Inc(NASDAQ-PDLI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PDLI股票新闻,以帮助您做出投资决策。